But as Raw Story reported, Luna’s husband holds significant investments in that very same research field — a revelation the Florida Congresswoman has chosen to hide.
Luna’s husband owns between $1,001 and $15,000 of stock in Lineage Cell Therapeutics, whose website proclaims its “proprietary cell-based therapy platform.”
DCCC Spokesperson Lauryn Fanguen:
“Hypocrisy is the name of the game for Anna Paulina Luna. Time and time again she says one thing and does another, lining her own pockets along the way. It’s hardly shocking how quickly Luna’s supposed deeply-held moral beliefs fall away when there’s a profit to be made.”
Rep. Anna Paulina Luna (R-FL) and her husband are suing the federal government, alleging COVID vaccine requirements in the military violated their religious beliefs because the therapy was developed using embryonic stem cells.
But Luna’s husband, Andrew Gamberzky, who resigned from the Air National Guard over the issue, also invests in a company that uses human embryonic stem cells to treat disabilities, according to Luna’s most recent congressional financial disclosure.
Gamberzky owns between $1,001 and $15,000 of stock in Lineage Cell Therapeutics. The California-based company says it intends to “pioneer a new branch of medicine based on transplanting specific cell types to patients with serious medical conditions,” such as paralysis.
That, according to corporate filings with the Securities and Exchange Commission, includes the use of embryonic stem cells derived from human embryos.
Luna’s office did not immediately respond to a request for comment.
Earlier this year — before Luna and Gamberzky filed the lawsuit — Raw Story first reported on Gamberzky’s ownership of Lineage Cell Therapeutics stock in the context of Luna’s staunch anti-abotion position.
Luna spokeswoman Edie Heipel subsequently said in an email to Raw Story that “Rep. Luna’s positions on this issue are blatantly clear” and that “she has no and has never had affiliation” with Lineage Cell Therapeutics “to include owning stock”.
Heipel did not respond to several follow-up questions, including why Luna’s husband purchased Lineage Cell Therapeutics stock, what she thinks of her husband’s stock holding and whether he plans to sell it.
Congressional financial disclosures, which require members of Congress to detail stock trades made by themselves, their spouses and dependent children, offer no indication that Gamberzky sold his Lineage Cell Therapeutics.
